NCT04528290View on ClinicalTrials.gov

A Study to Evaluate the Relative Bioavailability of a Pediatric Granule Formulation of Ozanimod in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

October 7, 2020

Primary Completion Date

May 19, 2021

Study Completion Date

June 1, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

Ozanimod

Ozanimod capsule formulation of 0.92mg

DRUG

Ozanimod

Ozanimod, granule formulation of 0.92mg

Trial Locations (1)

78744

PPD Phase 1 Clinic, Austin

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY